L'Oreal CO ADR (LRLCY)

$84.41 0.91 (1.07%)

15:59 EST LRLCY Stock Quote Delayed 30 Minutes

15 European Dividend Aristocrats to Diversify Your Portfolio

By Derek English Jul 21, 2021

Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out.

3 Cosmetics Stocks to Freshen Up Your Holdings

Has Valeant Pharmaceuticals Intl Inc (VRX) Stock Finally Bottomed?

3 Stocks to Watch on Monday: Pandora Media Inc (P), GrubHub Inc (GRUB) and Nestle SA (ADR) (NSRGY)

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 115,081

Day's Range $84.26 - $85.67

52-Week Range $70.12 - $97.48

Dividend & Yield $0.67 (0.79%)

LRLCY Stock Predictions, Articles, and L'Oreal CO ADR News

From InvestorPlace
From the Web

Valeant Pharmaceuticals Intl Inc (VRX) Stock Isn’t Healed by Paulson’s Presence

By James Brumley, InvestorPlace Feature Writer Jun 19, 2017

Valeant Pharmaceuticals (VRX) finds relief as John Paulson joins the board, but what can he really do to help VRX stock holders?

Don’t Buy the Valeant Pharmaceuticals Intl Inc (VRX) Stock Hype

By James Brumley, InvestorPlace Feature Writer Jun 8, 2017

VRX stock has emerged as one of Thursday's big winners, but it would be wise to crunch the numbers of the deal Valeant Pharmaceuticals just made.

Valeant Pharmaceuticals Intl Inc (VRX) Stock Won’t Keep This Rally Up

By Vince Martin, InvestorPlace Contributor May 8, 2017

Valeant earnings are due out Tuesday morning, but it would take a laundry list of good news to sustain the rally in VRX stock.

Will Valeant Shareholders Get ANYTHING? (VRX)

By Dana Blankenhorn, InvestorPlace Contributor Mar 14, 2017

Bill Ackman has abandoned Valeant (VRX), which has almost $30 billion in debt. VRX stock seems to be going through a slow liquidation.

The “New” Valeant Pharmaceuticals Intl Inc (VRX) Stock Is a Crock

By Will Ashworth, InvestorPlace Contributor Mar 7, 2017

Valeant Pharmaceuticals (VRX) might have a shiny new turnaround plan, but VRX stock is anything but new and improved.

Should You Buy Valeant Pharmaceuticals Intl Inc (VRX) Stock? 3 Pros, 3 Cons

By Ian Bezek, InvestorPlace Contributor Jan 24, 2017

Has Valeant Pharmaceuticals (VRX) turned the corner with its latest asset sales? Or is VRX stock still heading ever closer to zero?

Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Breakup Gold

By Dana Blankenhorn, InvestorPlace Contributor Jan 10, 2017

Valeant Pharmaceuticals' (VRX) asset sales could be the start of a breakup. Speculators who get into VRX stock now can still reap rewards.

Alphabet Unit Verily, L'Oreal Collaborate On Skin Health: What You Need To Know

From Benzinga Jan 21, 2022

Alphabet, Inc.'s (NASDAQ: GOOGL) (NASDAQ: GOOG) subsidiary Verily, a precision health company, and L'Oréal S.A. (Pink: LRLCY) announced Thursday a strategic...

This Beauty-Care Company Is Working on a Turnaround. The Stock Is Looking Attractive.

From Barron's Sep 3, 2021

German personal-care products company Beiersdorf is back on track with growth in the first half of the year.

Zhihu's Revenue Rose 144% Year-on-Year

From Benzinga Aug 17, 2021

Key points: Zhihu’s revenue rose 144% year-on-year in its latest quarterly results, fueled by a big increase in ‘content commerce solutions’ One of the company...

Everyone Is Talking About the Metaverse. These Companies Have an Early Lead.

From Barron's Aug 13, 2021

Corporate mentions of the metaverse are up five times this year. Here are companies with the early lead.

Buy Glaxo Stock Because Its Turnaround Could Be Accelerated

From Barron's Jul 31, 2021

The long-awaited turnaround for British drugmaker GlaxoSmithKline could soon be at hand, with some nudging from activist hedge fund Elliott Management.

Glaxo Is Attempting a Turnaround. An Activist Wants to Accelerate It. Buy the Stock.

From Barron's Jul 29, 2021

The long-awaited turnaround for British drugmaker GlaxoSmithKline could soon be at hand, with some nudging from activist hedge fund Elliott Management.